Skip to content

Author

N. Doki

We have 5 of 553 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Clonal hematopoiesis in long-term survivors after allogeneic hematopoietic cell transplantation: associations with active chronic graft-versus-host disease, donor age, and transplantation for chronic myeloid leukemia.

Clonal hematopoiesis (CH) in long-term survivors of allogeneic hematopoietic cell transplant (HCT) remains largely understudied. Using targeted sequencing, we analyzed peripheral blood samples from 101 patients who survived without relapse for more than 10 years after HCT. The median interval from HCT to sample collect...

T. Toya, D. Sadato, C. Hirama et al. · 0 citations
Oct 2026

Neutrophil Engraftment Timing after Single-Unit Cord Blood Transplantation as a Prognostic Marker of Transplant Outcomes Influenced by GVHD Prophylaxis: A nationwide, retrospective study by the Japanese Society for Transplantation and Cellular Therapy.

BACKGROUND Delayed neutrophil recovery after cord blood transplantation (CBT) has been established as an adverse prognostic factor; however, the prognostic impact of early neutrophil engraftment remains unclear. OBJECTIVE To investigate the association between neutrophil engraftment (NE) timing and transplant outcome...

Takashi Oyama, Mitsuhiro Yuasa, Y. Miyamoto et al. · 0 citations
Case report Open access Aug 2026

Case Report: Immune-directed post-transplant maintenance with low-dose gemtuzumab ozogamicin and stepwise donor lymphocyte infusion in acute myeloid leukemia with t(1;3)(p36.3;q21)

This case suggests that sequential low-dose GO followed by stepwise DLI may support durable remission when used as a post-transplant maintenance strategy in chemo-refractory AML with adverse cytogenetics, such as t(1;3)(p36.3;q21).

Fumihiko Ouchi, Y. Najima, K. Haraguchi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.